GlassScriptPhysician profile
Amber Campbell
NPI 1891247441
$10,993.10
in general payments reported to CMS, 2019-2025
52 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $852 · 2022: $1,374 · 2023: $2,476 · 2024: $3,333 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,766.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,037.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,017.99 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $812.96 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lundbeck LLC | $705.17 | 2022-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $694.34 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $382.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $348.14 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $261.79 | 2021-2024 | Spravato |
| Biohaven Pharmaceuticals, INC. | $247.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $226.08 | 2022-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $190.95 | 2022 | |
| Pfizer INC. | $177.92 | 2021-2025 | |
| Astellas Pharma US INC | $170.98 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.43 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $163.21 | 2023-2025 | Cologuard Collection Kit |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $162.46 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.71 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $151.66 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $145.54 | 2024-2025 | Voquezna |
| Corium, LLC | $135.51 | 2024-2025 | Azstarys |
| Ani Pharmaceuticals, INC. | $121.36 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $118.90 | 2021-2025 | Belsomra, Capvaxive, Steglatro |
| Sumitomo Pharma America, INC. | $114.67 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $114.53 | 2021-2025 | Trintellix |
| Amgen INC. | $110.01 | 2022-2025 | Repatha, Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $106.17 | 2022-2025 | |
| Optinose US, INC. | $88.55 | 2024-2025 | |
| Esperion Therapeutics, INC. | $73.96 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.39 | 2022-2024 | Trulance, Xifaxan |
| Dexcom, INC. | $60.76 | 2023-2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $60.68 | 2024-2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $57.52 | 2023-2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $53.27 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Teva Pharmaceuticals USA, INC. | $39.31 | 2021-2023 | Austedo Xr |
| Mylan Specialty L.P. | $38.83 | 2022-2024 | Yupelri |
| Amarin Pharma, INC. | $38.60 | 2021-2022 | |
| Corcept Therapeutics | $38.17 | 2021 | |
| Ironshore Pharmaceuticals INC. | $37.36 | 2024 | |
| Sunovion Pharmaceuticals INC. | $35.95 | 2022 | |
| Aimmune Therapeutics, INC. | $35.32 | 2025 | Zenpep |
| Radius Health, INC. | $30.81 | 2023 | Tymlos |
| Idorsia Pharmaceuticals US INC | $26.07 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $24.08 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $21.11 | 2024 | Opsumit, Uptravi |
| Tolmar, INC. | $18.61 | 2025 | Jatenzo |
| Hologic Sales and Service, LLC | $18.46 | 2024 | Acessa Provu System |
| Sanofi-Aventis U.S. LLC | $17.23 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.10 | 2025 | Jornay Pm |
| Ibsa Pharma INC. | $15.46 | 2021 | |
| Bausch Health US, LLC | $14.57 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.52 | 2021 | |
| Lucid Diagnostics INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.